Article Information
History
- November 9, 2021.
Article Versions
- Version 1 (October 12, 2021 - 19:13).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Prof E. Wesley Ely, MD1,2,*,
- Prof Athimalaipet V. Ramanan, FRCP3,4,
- Cynthia E. Kartman, RN5,
- Stephanie de Bono, MD5,
- Ran Liao, PhD5,
- Maria Lucia B. Piruzeli, MD5,
- Jason D. Goldman, MD6,7,
- Prof José Francisco Kerr Saraiva, MD8,
- Sujatro Chakladar, PhD5,
- Prof Vincent C. Marconi, MD9,10 and
- on behalf of the COV-BARRIER Study Group
- 1Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University Medical Center, Nashville, TN, USA
- 2Tennessee Valley Veteran’s Affairs Geriatric Research Education Clinical Center (GRECC), Nashville, TN, USA
- 3Translational Health Sciences, University of Bristol, Bristol, UK
- 4Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK
- 5Eli Lilly and Company, Indianapolis, IN, USA
- 6Swedish Center for Research and Innovation, Swedish Medical Center, Providence St. Joseph Health Seattle, WA, USA
- 7Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, WA, USA
- 8Instituto de Pesquisa Clínica de Campinas (IPECC), Campinas, SP, Brazil
- 9Emory University School of Medicine, Rollins School of Public Health, Emory Vaccine Center Atlanta, GA, USA
- 10Atlanta Veterans Affairs Medical Center, Decatur, GA, USA
- ↵* Corresponding author; email: wes.ely{at}vumc.org